← Back to Screener
Tyra Biosciences, Inc. Common Stock (TYRA)
Price$34.37
Favorite Metrics
Price vs S&P 500 (26W)154.27%
Price vs S&P 500 (4W)-13.77%
Market Capitalization$1.92B
All Metrics
Book Value / Share (Quarterly)$4.83
P/TBV (Annual)1.87x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.77
Price vs S&P 500 (YTD)31.12%
EPS (TTM)$-2.01
10-Day Avg Trading Volume1.16M
EPS Excl Extra (TTM)$-2.01
EPS (Annual)$-2.01
ROI (Annual)-46.28%
Cash / Share (Quarterly)$4.77
ROA (Last FY)-42.44%
EBITD / Share (TTM)$-2.22
ROE (5Y Avg)-27.10%
Cash Flow / Share (Annual)$-1.77
P/B Ratio7.39x
P/B Ratio (Quarterly)5.41x
Net Income / Employee (Annual)$-1
ROA (TTM)-38.40%
EPS Incl Extra (Annual)$-2.01
Current Ratio (Annual)14.67x
Quick Ratio (Quarterly)14.25x
3-Month Avg Trading Volume0.90M
52-Week Price Return313.01%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.18
52-Week High$40.65
EPS Excl Extra (Annual)$-2.01
CapEx CAGR (5Y)-14.58%
26-Week Price Return163.02%
Quick Ratio (Annual)14.25x
13-Week Price Return21.78%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.67x
Enterprise Value$1,838.128
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.77
3-Month Return Std Dev50.78%
Net Income / Employee (TTM)$-1
ROE (Last FY)-46.28%
EPS Basic Excl Extra (Annual)$-2.01
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.01
ROI (TTM)-41.17%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$6.09
Price vs S&P 500 (52W)277.91%
Year-to-Date Return35.26%
5-Day Price Return-0.17%
EPS Normalized (Annual)$-2.01
ROA (5Y Avg)-25.24%
Month-to-Date Return-7.15%
Cash Flow / Share (TTM)$-1.38
EBITD / Share (Annual)$-2.22
ROI (5Y Avg)-27.10%
EPS Basic Excl Extra (TTM)$-2.01
P/TBV (Quarterly)2.17x
P/B Ratio (Annual)5.41x
Book Value / Share (Annual)$4.83
Price vs S&P 500 (13W)18.92%
Beta0.82x
Revenue / Share (TTM)$0.00
ROE (TTM)-41.17%
52-Week Low$7.80
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.40
4.38
4.39
4.39
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TYRATyra Biosciences, Inc. Common Stock | — | — | — | — | $34.37 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Tyra Biosciences is a clinical-stage biotechnology company developing precision medicines targeting FGFR (Fibroblast Growth Factor Receptor) biology through its proprietary SNAP platform, which enables rapid drug discovery with optimized potency, selectivity, and safety profiles. The pipeline includes three clinical-stage small molecules (TYRA-300, TYRA-200, TYRA-430) designed to overcome the toxicity and resistance liabilities of first-generation FGFR inhibitors.